COMMUNIQUÉS West-GlobeNewswire

Humacyte Receives Symvess® Purchase Commitment for Clinical Evaluation and Outreach Program in the Kingdom of Saudi Arabia
19/03/2026
- Purchase commitment is for a minimum of $1.475 million of Symvess product - DURHAM, N.C., March 19, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing [...]
Primary Care Physician Use of Counterpart Assistant Associated with 18%–22% Fewer Flu-Related Acute Care Events Among COPD and CHF Patients
19/03/2026
New Counterpart Health whitepaper finds patients whose primary care physicians (PCP) used Counterpart Assistant’s flu-related clinical insight were 1.89 times more likely to receive a flu vaccination — and patients with [...]
Quoin Pharmaceuticals to Announce Corporate Update and Fourth Quarter and Full-Year 2025 Financial Results on Thursday, March 26, 2026
19/03/2026
ASHBURN, Va., March 19, 2026 (GLOBE NEWSWIRE) -- Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) (the "Company" or "Quoin"), a late clinical-stage specialty pharmaceutical company focused on rare and orphan diseases, today [...]
Humacyte, Inc. Announces Pricing of $20 Million Registered Direct Offering of Common Stock
19/03/2026
Net proceeds from the offering will fund the commercialization of Symvess® in the vascular trauma indication and provide funding beyond key milestones such as the upcoming read-out of Phase 3 results in hemodialysis The [...]
Mereo BioPharma Reports Full Year 2025 Financial Results and Provides Corporate Highlights
19/03/2026
Additional data analyses from Orbit and Cosmic Phase 3 studies of setrusumab (UX143) in osteogenesis imperfecta ongoing Cash of $41.0 million as of December 31, 2025, expected to provide runway into mid-2027 LONDON, [...]
MedicAlert Foundation, Sickle Cell Disease Association of America, Inc. (SCDAA), and Fulcrum Therapeutics Partner to Accelerate Emergency Department Access to Critical Care Information for People Living with Sickle Cell Disease
19/03/2026
Three-year collaboration is aimed at enhancing a key aspect of sickle cell management: expediting care during a pain crisis CAMBRIDGE, Mass., March 19, 2026 (GLOBE NEWSWIRE) -- MedicAlert Foundation, the leading [...]
INmune Bio’s MINDFuL Trial Featured at AD/PD 2026 Plenary as Successful Example of How to Approach Clinical Trials Targeting Inflammation in Early Alzheimer’s Disease
19/03/2026
Plenary Presentation Highlights How Aligning Inflammatory Biomarker Enrichment with Mechanism of Action Offers a Blueprint for Success in Alzheimer’s Drug Development Boca Raton, FL, March 19, 2026 (GLOBE NEWSWIRE) -- [...]
Taysha Gene Therapies Reports Full-Year 2025 Financial Results and Provides Corporate Update
19/03/2026
Dosed multiple Rett syndrome patients in REVEAL pivotal trial of TSHA-102, with enrollment advancing across multiple sites; on track to complete dosing in Q2 2026 Received FDA clearance to initiate ASPIRE trial in three [...]
Cylinder Health appoints Terry Boch as CEO as demand grows for digestive health solutions
19/03/2026
Health care technology executive brings more than three decades of leadership experience and a personal connection to digestive health. CHICAGO, March 19, 2026 (GLOBE NEWSWIRE) -- Cylinder Health today announced the [...]
InflaRx Reports Full Year 2025 Results and Highlights Key Achievements and Expected Milestones
19/03/2026
Promising Phase 2a data announced for izicopan, underscoring its potential as a meaningfully differentiated, effective and safe oral inhibitor of C5aR Substantial progress made toward Phase 2b readiness for izicopan in [...]
CervoMed Announces New Data at the AD/PD™ 2026 Scientific Conference that Reinforce Neflamapimod’s Positive Effects in Dementia with Lewy Bodies (DLB) in Patients without Alzheimer’s Disease Co-Pathology
19/03/2026
New analyses show DLB patients with lower plasma pTau181 levels — indicating an earlier stage of disease and absence of Alzheimer’s disease (AD) co-pathology — experienced greater clinical benefit with neflamapimod in [...]
Plus Therapeutics to Present New Analysis at ISPOR Showing CNSide® May Reduce Leptomeningeal Metastases Healthcare Costs by 40%
19/03/2026
Health economics analysis highlights the economic burden of late-stage leptomeningeal metastases (LM) and the potential value of earlier diagnosis using CNSide as it enters U.S. commercialization HOUSTON, March 19, 2026 [...]
Context Therapeutics Announces Poster Presentation at the American Association for Cancer Research (AACR) Annual Meeting 2026
19/03/2026
PHILADELPHIA, March 19, 2026 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a clinical-stage biopharmaceutical company advancing T cell engaging (“TCE”) bispecific antibodies [...]
Leading Independent Proxy Advisory Firm ISS Recommends Aptose Biosciences Shareholders Vote “FOR” Proposed Plan of Arrangement with Hanmi Pharmaceutical
19/03/2026
SAN DIEGO and TORONTO, March 19, 2026 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“ Aptose ” or the “ Company ”) (TSX: APS; OTC: APTOF) today announced that Institutional Shareholder Services (“ISS”), a leading [...]
Biogen to Present New Late-Breaking Litifilimab Phase 2 AMETHYST Data in Cutaneous Lupus Erythematosus at 2026 American Academy of Dermatology Annual Meeting
19/03/2026
Late-breaking AMETHYST Part A study results to be presented, showing safety and efficacy of litifilimab in cutaneous lupus erythematosus (CLE) Litifilimab was recently granted Breakthrough Therapy Designation by the FDA [...]
NeuroRPM to Deploy AI-Enabled Digital Biomarker Monitoring for Annovis Bio's Parkinson's Disease Clinical Trial
19/03/2026
WASHINGTON, D.C., March 19, 2026 (GLOBE NEWSWIRE) -- NeuroRPM , a digital health company focused on Parkinson’s disease monitoring, today announced that its FDA-cleared wearable platform will be used for digital [...]
Collegium to Acquire AZSTARYS® from Corium Therapeutics, Strengthening Position in ADHD and Accelerating Growth Trajectory
19/03/2026
– Adds Highly Complementary and Differentiated Medicine with Significant Growth Potential to Collegium’s Existing ADHD Portfolio – – Enables Greater Impact Across ADHD Patient Communities – – AZSTARYS Expected to [...]
Immutep Reports Progress from Phase I Study of LAG-3 Agonist for Autoimmune Diseases
19/03/2026
Immutep has completed the single ascending dose (SAD) portion of its IMP761 study IMP761 was well tolerated across all dose levels IMP761 data and Phase I results will be presented at the EULAR conference on 4 June 2026 [...]
BioRestorative Therapies to Present Positive Phase 2 Blinded Data for BRTX-100 Demonstrating Meaningful Improvements in Pain and Function in Chronic Lumbar Disc Disease
19/03/2026
New blinded data from ~45 patients to date in key pain and function scales and safety and tolerability of the Company’s proprietary hypoxic-cultured mesenchymal stem cells to be unveiled on March 28th at the 2026 [...]

Pages